NASDAQ: MEDSTrxade Health Inc Stock
$0.27-0.02 (-6.9%)
Updated May 26, 2023
MEDS Price
$0.27
Fair Value Price
$0.42
Market Cap
$2.80M
52 Week Low
$0.25
52 Week High
$1.79
P/E
-0.76x
P/B
4.27x
P/S
0.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.46M
Earnings
-$3.19M
Gross Margin
54.3%
Operating Margin
-26.71%
Profit Margin
-30.5%
Debt to Equity
5.16
Operating Cash Flow
-$1M
Beta
0.59
Next Earnings
Jul 24, 2023
Ex-Dividend
N/A
Next Dividend
N/A
MEDS Overview
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MEDS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MEDS ($0.27) is undervalued by 34.57% relative to our estimate of its Fair Value price of $0.42 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MEDS ($0.27) is significantly undervalued by 34.57% relative to our estimate of its Fair Value price of $0.42 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MEDS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MEDS due diligence checks available for Premium users.
Be the first to know about important MEDS news, forecast changes, insider trades & much more!
MEDS News
Valuation
MEDS fair value
Fair Value of MEDS stock based on Discounted Cash Flow (DCF)
Price
$0.27
Fair Value
$0.42
Undervalued by
35.53%
MEDS ($0.27) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MEDS ($0.27) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MEDS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MEDS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.76x
Industry
9.51x
Market
54.23x
MEDS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.27x
Industry
1.28x
MEDS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MEDS's financial health
Profit margin
Revenue
$2.2M
Net Income
-$678.0k
Profit Margin
-30.2%
MEDS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MEDS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.0M
Liabilities
$3.4M
Debt to equity
5.16
MEDS's short-term liabilities ($2.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MEDS's short-term assets ($2.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MEDS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MEDS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$931.5k
Investing
$333.2k
Financing
$681.3k
MEDS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MEDS vs Pharmaceutical Retailer Stocks
Trxade Health Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.